PCSA (Processa Pharmaceuticals, Inc. Common)
Insider Trading Activity
Every open-market purchase and sale reported by PCSA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | George K Ng | Chief Executive Officer | M | — | — |
| 2026-07-30 | SHEILA GUJRATHI | Director | A | — | — |
| 2026-07-28 | Geraldine Pannu | Director | A | — | — |
| 2026-07-28 | Patrick Lin | Chief Business - Strategy Off | A | — | — |
| 2026-07-28 | James R Neal | Director | A | — | — |
| 2026-07-28 | RUSSELL SKIBSTED | Chief Financial Officer | A | — | — |
| 2026-07-28 | George K Ng | Chief Executive Officer | A | — | — |
| 2026-07-28 | Justin W Yorke | Director | A | — | — |
| 2026-07-28 | Khoso Baluch | Director | A | — | — |
| 2026-07-28 | Wendy Guy | Chief Administrative Officer | A | — | — |
| 2026-07-01 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | — | — |
| 2026-07-01 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-07-01 | Patrick Lin | Chief Business - Strategy Off | Buy | — | — |
| 2026-07-01 | David Young | Pres. Research & Development | Buy | — | — |
| 2026-07-01 | Wendy Guy | Chief Administrative Officer | Buy | — | — |
| 2026-06-16 | Patrick Lin | Chief Business - Strategy Off | Buy | — | — |
| 2026-06-16 | Wendy Guy | Chief Administrative Officer | Buy | — | — |
| 2026-06-16 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-06-16 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | — | — |
| 2026-06-16 | David Young | Pres. Research & Development | Buy | — | — |
| 2026-06-01 | Patrick Lin | Chief Business - Strategy Off | Buy | — | — |
| 2026-06-01 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | — | — |
| 2026-06-01 | David Young | Pres. Research & Development | Buy | — | — |
| 2026-06-01 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-06-01 | Wendy Guy | Chief Administrative Officer | Buy | — | — |
| 2026-05-19 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | — | — |
| 2026-05-19 | Sian Bigora | Chief Development Officer | Buy | — | — |
| 2026-05-19 | Patrick Lin | Chief Business - Strategy Off | Buy | — | — |
| 2026-05-19 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-05-19 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-05-19 | Wendy Guy | Chief Administrative Officer | Buy | — | — |
| 2026-05-19 | David Young | Pres. Research & Development | Buy | — | — |
| 2026-05-01 | Sian Bigora | Chief Development Officer | Buy | — | — |
| 2026-05-01 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | — | — |
| 2026-05-01 | Wendy Guy | Chief Administrative Officer | Buy | — | — |
| 2026-05-01 | David Young | Pres. Research & Development | Buy | — | — |
| 2026-05-01 | Patrick Lin | Chief Business - Strategy Off | Buy | — | — |
| 2026-05-01 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-04-17 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | — | — |
| 2026-04-17 | Sian Bigora | Chief Development Officer | Buy | — | — |
| 2026-04-17 | Wendy Guy | Chief Administrative Officer | Buy | — | — |
| 2026-04-17 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-04-17 | David Young | Pres. Research & Development | Buy | — | — |
| 2026-04-17 | Patrick Lin | Chief Business - Strategy Off | Buy | — | — |
| 2026-04-02 | James R Neal | Director | Buy | — | — |
| 2026-04-01 | Geraldine Pannu | Director | Buy | — | — |
| 2026-04-01 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | — | — |
| 2026-04-01 | Sian Bigora | Chief Development Officer | Buy | — | — |
| 2026-04-01 | George K Ng | Chief Executive Officer | Buy | — | — |
| 2026-04-01 | Wendy Guy | Chief Administrative Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Pres. Research & Development | 22,971 | — |
| — | Chief Executive Officer | 17,892 | — |
| — | Chief Financial Officer | 16,689 | — |
| — | Chief Business - Strategy Off | 14,853 | — |
| — | Chief Administrative Officer | 14,727 | — |
| — | Chief Development Officer | 7,748 | — |
| — | 10%+ Owner | 3,044 | — |
| — | Director | 2,528 | — |
| — | Director | 2,391 | — |
| — | Director | 1,021 | — |
| — | Director | 849 | — |
| — | Director | 387 | — |
| — | Chief Operating Officer | 345 | — |
| — | Director | 281 | — |
| — | Chief Financial Officer | 271 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PCSA quote page; the site-wide leaderboard is on the insider transactions hub.